Ceregene and Genzyme in partnership for Parkinson's

Published: 22-Jun-2007

Ceregene and Genzyme have entered into a partnership for the development and commercialisation of CERE-120, Ceregene\'s proprietary lead program for the treatment of Parkinson\'s disease.


Ceregene and Genzyme have entered into a partnership for the development and commercialisation of CERE-120, Ceregene's proprietary lead program for the treatment of Parkinson's disease.

Genzyme will pay Ceregene US$25m up-front. Ceregene will be entitled to development-related milestone payments of up to $125m and 50% reimbursement of the worldwide Phase 3 development costs. Genzyme will gain marketing rights in all markets outside of the US and Canada. Ceregene will retain exclusive rights to CERE-120 in the US and Canada.

'CERE-120, currently undergoing a controlled Phase 2 trial in the US that is being partially funded by the Michael J. Fox Foundation, has demonstrated strong clinical and preclinical data to date and may have the ability to both improve Parkinson's disease symptoms and slow the disease progression,' said Jeffrey Ostrove, president and ceo of Ceregene.

In a complementary program, Genzyme is conducting a separate Phase 1-2 clinical trial of a gene therapy for Parkinson's disease designed to restore the therapeutic effectiveness of levo-Dopa by enhancing the brain's ability to convert it into dopamine.

See more

You may also like

Finance

BARDA awards $37.6m contract to Sanofi to supply Leukine (sargramostim) for potential public health emergency

Read more
We are pleased to be able to partner with BARDA to support public health, says Sanofi

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Finance

BARDA awards $37.6m contract to Sanofi to supply Leukine (sargramostim) for potential public health emergency

We are pleased to be able to partner with BARDA to support public health, says Sanofi
Research & Development

Sanofi Genzyme forms multiple sclerosis research alliance with Johns Hopkins School of Medicine

To focus on understanding the underlying causes of disease progression in MS
Research & Development

Genzyme collaborates with Ablynx on multiple sclerosis project

Genzyme's research efforts aim to address the underlying causes of MS disease progression
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
Research & Development

Genzyme teams up with Voyager Therapeutics to develop AAV gene therapies for CNS disorders

Will make an upfront payment of US$100m to Voyager
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Meeting regulatory expectations

Best practice and meeting the expectations of regulators on the use of plant isolates, bioburden strategies, rapid ID methods, auditing environmental controls and deviation management are topics taxing microbiologists. Susan Birks reports on issues discussed at the Pharmig conference
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Subscribe now